2010 Sep; 42(7) : 2731-9 Microdystrophin Delivery in Dystrophin-Deficient (mdx) Mice by Genetically-Corrected Syngeneic MSCs Transplantation. Xiong F, Xu Y, Zheng H, Lu X, Feng S, Shang Y, Li Y, Zhang Y, Jin S, Zhang C Abstract Cell transplantation and gene therapy are two promising therapeutical approaches for the treatment on Duchenne Muscular Dystrophy (DMD).…

2010 Aug 1;24(4):237-47 Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y Abstract Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular…

2010 Aug 24; Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice. Verma M, Asakura Y, Hirai H, Watanabe S, Tastad C, Fong GH, Ema M, Call JA, Lowe DA, Asakura A Abstract Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disease caused by mutations in the gene coding for…

2010 Aug 1;24(4):237-47 Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y Abstract Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular…

2010 Aug;69(8):771-6 Targeting fibrosis in Duchenne muscular dystrophy. Zhou L, Lu H Abstract Duchenne muscular dystrophy (DMD) is the most common genetic muscle disease affecting 1 in 3,500 live male births. It is an X-linked recessive disease caused by a defective dystrophin gene. The disease is characterized by progressive limb weakness, respiratory and cardiac failure,…

2010 Jul;160(6):1550-60 Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D’Angelo G, Cattaneo D, Brunelli S, Clementi E Abstract Current therapies for muscular dystrophy are based on corticosteroids. Significant side effects associated with these…

2010;52(5):399-406 Structure of neuromuscular junctions and differentiation of striated muscle fibers of mdx mice after bone marrow stem cells therapy. Sokolova AV, Zenin VV, MikhaÄlov VM Mdx mice are a model of Duchenne muscular dystrophy caused by deficiency of dystrophin. Muscles of mdx mice are characterized by high levels of striated muscle fibers death and,…

2010 Jul;31(20):5385-96 Ex vivo expansion of human circulating myogenic progenitors on cluster-assembled nanostructured TiO2. Belicchi M, Erratico S, Razini P, Meregalli M, Cattaneo A, Jacchetti E, Farini A, Villa C, Bresolin N, Porretti L, Lenardi C, Milani P, Torrente Y Abstract Ex vivo expansion of hematopoietic stem cells has been explored in the fields of…

2010;260(2):75-82. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Ichim TE, Alexandrescu DT, Solano F, Lara F, Campion Rde N, Paris E, Woods EJ, Murphy MP, Dasanu CA, Patel AN, Marleau AM, Leal A, Riordan NH. Medistem Inc., San Diego, CA 92122, USA. Abstract Duchenne muscular dystrophy (DMD) is a lethal…

2010 Jun;41(6):746-50 Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. Kang PB, Lidov HG, White AJ, Mitchell M, Balasubramanian A, Estrella E, Bennett RR, Darras BT, Shapiro FD, Bambach BJ, Kurtzberg J, Gussoni E, Kunkel LM Abstract We report a boy who received two allogeneic stem cell transplantations from umbilical cord donors…